LEO Pharma A/S

The US Food and Drug Administration’s approval decisions for novel agents will come from different divisions in the second half of 2025, compared to the first half, the Pink Sheet ’s US FDA Performan

With 22 novel agents approved in the first six months of 2025, the US FDA is already behind its average approval count for the first half of the year, and the user fee calendar for the second half doe

Leo Pharma’s mission to be the partner of choice in the field of medical dermatology has been bolstered by an eye-catching deal to commercialize and further develop Boehringer Ingelheim’s flagship ski

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. JCR Adds $825m Gene Therapy Tech D